Free Trial

Eupraxia Pharmaceuticals (EPRX) Competitors

Eupraxia Pharmaceuticals logo
$5.54 +0.48 (+9.49%)
Closing price 03:59 PM Eastern
Extended Trading
$5.67 +0.13 (+2.35%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EPRX vs. CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, KALV, AMLX, and AVBP

Should you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

Eupraxia Pharmaceuticals vs. Its Competitors

Cronos Group (NASDAQ:CRON) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, Eupraxia Pharmaceuticals had 6 more articles in the media than Cronos Group. MarketBeat recorded 7 mentions for Eupraxia Pharmaceuticals and 1 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.00 beat Eupraxia Pharmaceuticals' score of 0.61 indicating that Cronos Group is being referred to more favorably in the media.

Company Overall Sentiment
Cronos Group Positive
Eupraxia Pharmaceuticals Positive

Cronos Group has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$117.61M6.79$41.08M$0.1315.92
Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.29

Eupraxia Pharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 98.56%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Eupraxia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

8.7% of Cronos Group shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cronos Group has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Cronos Group has a net margin of 39.69% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat Eupraxia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group39.69% -0.07% -0.07%
Eupraxia Pharmaceuticals N/A -367.73%-112.23%

Summary

Cronos Group beats Eupraxia Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EPRX vs. The Competition

MetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$181.94M$3.06B$5.72B$9.48B
Dividend YieldN/A2.38%4.59%3.98%
P/E Ratio-7.2920.8627.9219.95
Price / SalesN/A321.12441.30102.64
Price / CashN/A43.2336.5558.97
Price / BookN/A8.308.635.90
Net Income-$25.50M-$55.19M$3.24B$258.42M
7 Day Performance2.40%5.07%3.22%1.94%
1 Month Performance27.36%17.61%10.72%12.02%
1 Year Performance113.90%7.03%34.94%20.81%

Eupraxia Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EPRX
Eupraxia Pharmaceuticals
2.5079 of 5 stars
$5.54
+9.5%
$11.00
+98.6%
+97.8%$181.94MN/A-7.2929News Coverage
Analyst Forecast
Gap Up
High Trading Volume
CRON
Cronos Group
2.4412 of 5 stars
$2.02
-2.4%
N/A-16.1%$798.36M$117.61M15.54450News Coverage
Positive News
QURE
uniQure
1.8303 of 5 stars
$13.96
-4.1%
$37.82
+170.9%
+91.4%$796.99M$27.12M-3.18500Upcoming Earnings
OCS
Oculis
1.5945 of 5 stars
$17.89
-1.5%
$35.33
+97.5%
+57.0%$792.91M$780K-6.782
ANAB
AnaptysBio
1.4404 of 5 stars
$26.63
-1.2%
$42.38
+59.1%
-26.9%$791.79M$111.87M-5.49100Analyst Forecast
Gap Up
BGM
BGM Group
N/A$8.90
+10.1%
N/AN/A$785.55M$25.10M0.00298News Coverage
Gap Up
High Trading Volume
CRMD
CorMedix
2.9016 of 5 stars
$11.37
+0.1%
$17.14
+50.8%
+140.6%$770.49M$43.47M51.6830Positive News
VIR
Vir Biotechnology
3.6767 of 5 stars
$5.30
-3.6%
$30.25
+470.8%
-42.6%$760.31M$74.21M-1.26580
KALV
KalVista Pharmaceuticals
4.1095 of 5 stars
$15.17
-0.3%
$26.29
+73.3%
+1.1%$760.30MN/A-4.11100High Trading Volume
AMLX
Amylyx Pharmaceuticals
3.2906 of 5 stars
$8.12
-3.4%
$11.75
+44.7%
+328.1%$749.68M$87.37M-2.61200
AVBP
ArriVent BioPharma
2.2966 of 5 stars
$21.62
-1.1%
$39.29
+81.7%
+7.1%$748.23MN/A-5.7340Positive News
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:EPRX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners